Dr. Danielle Marie Feigenbaum, MD

Dr. Feigenbaum practices at Keck Hospital of USC in Los Angeles, California, part of University of Southern California.

Dr. Feigenbaum's NPI, 1558621904, was assigned on May 19, 2012. Dr. Feigenbaum graduated from University of Miami, Miller School of Medicine in 2011. Dr. Feigenbaum holds California license A123652.

Dr. Feigenbaum's primary practice is Keck Hospital of USC, at 1500 San Pablo Street, Los Angeles, CA 90033 in Los Angeles County. The practice phone is (323) 442-8656.

Dr. Feigenbaum's primary practice is Keck Hospital of USC in Los Angeles, California, part of University of Southern California. Dr. Feigenbaum is also affiliated with USC Verdugo Hills Hospital. The medical group on file is USC Care Medical Group. Dmand AI also links Dr. Feigenbaum to 1 more hospital, 1 group practice or clinic, 1 home health agency, 1 other site and 1 urgent care center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Feigenbaum practices, 7 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Feigenbaum's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Feigenbaum is board certified in neurology by the American Board of Psychiatry and Neurology. Dr. Feigenbaum is licensed in California.

Dmand AI lists essential tremor, fibromyalgia and chronic pain, lower back pain, migraine and chronic headache, muscle pain, fibromyalgia, and limb pain, parkinson's disease, restless legs syndrome and thoracic spine disorders among the conditions Dr. Feigenbaum treats.

CMS data shows 456 Medicare services from Dr. Feigenbaum across 4 procedure codes in 2024, for 188 Medicare patients. Medicare paid $36,332 for them.

CMS counts 188 Medicare patients who saw Dr. Feigenbaum in 2024. The largest group is 75 to 84, with 72 patients. 75% of them have high cholesterol, and 70% have high blood pressure. 39% are also on Medicaid. Their average risk score is 1.92, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Feigenbaum's median patient age at 74, with 53% women.

In 2024, Dr. Feigenbaum wrote 1,685 Medicare Part D claims for 185 patients. 87% of them were for generic drugs. CMS names the drug for 1,472 of them, across 27 drugs with 11 or more claims each, at $926,925 in total drug cost. In 2023, CMS named 1,379 claims across 30 drugs.

Dr. Feigenbaum accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Feigenbaum as offering telehealth.

Dmand AI links 1 paper to Dr. Feigenbaum in 2020. Dr. Feigenbaum's most frequent co-authors are Jordan Lam, MBBS, Darrin J. Lee, MD and Mark Andrew Liker, MD.

Dmand AI links Dr. Feigenbaum to 1 clinical trial. Conditions studied include Lewy Body Disease and Parkinson Disease.

CMS Open Payments shows 112 general payments to Dr. Feigenbaum from 8 drug and device companies from 2016 to 2025. Grants make up the largest share, 94% of the total. Medtronic USA, Inc. paid the most, $46,308.

Dr. Feigenbaum graduated from University of Miami, Miller School of Medicine in 2011.

Dr. Feigenbaum is in network with 7 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.